Deriva AI

Company Overview

Snapshot

Founded in March 2024 by Nizar Jubran, Deriva AI operates with 1–10 employees. The company has secured funding across one round from one investor, Hasoub Angels, and is currently in the Pre-Seed stage.

Business overview

Deriva AI develops an AI-based platform designed for genetic variant interpretation, leveraging a swarm of specialized agents to analyze scientific literature, clinical notes, figures, and multi-omic datasets. The platform applies continuously updated, gene-specific ACMG guidelines to produce transparent and auditable pathogenicity assessments with source citations rapidly. Serving the Health Tech & Life Sciences sector. The company focuses on medical decision support within digital healthcare, targeting the life sciences, biotechnology, and pharmaceutical industries.

Company Intelligence Q&A

When was Deriva AI founded?

Deriva AI was founded in March 2024 by Nizar Jubran.

What is Deriva AI's primary focus?

Deriva AI focuses on providing an AI-based platform for fast genetic variant interpretation, utilizing specialized agents to analyze diverse scientific and clinical data.

Which sector does Deriva AI operate in?

Deriva AI operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Decision Support.

What is the core technology behind Deriva AI's platform?

The core technology of Deriva AI's platform involves artificial intelligence and software platforms that use a swarm of specialized agents to ingest and analyze scientific and clinical data for genetic variant interpretation.

Which investor participated in Deriva AI's funding round?

In April 2025, Deriva AI received funding from Hasoub Angels in a Pre-Seed round.